Indications › Cancer
GLP‑1 drugs in cancer
Which incretin agents are being studied in cancer, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 16
- Active
- 15
- Results scheduled
- 1
- Molecules studied
- 3
- Sponsors
- 15
No GLP‑1 or incretin drug is FDA-approved for cancer. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for cancer, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 5 of the 16 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 11 still in early phases. 15 distinct sponsors are involved.
Molecules studied in this indication
mazdutide · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2028-03-01 | tirzepatide | Clinical Study of Local and Systemic Biological Impact of GLP1/GIP-Receptor Agonists in Patients With Breast Cancer: The CLARA Trial NCT07676331 · Universitaire Ziekenhuizen KU Leuven | P2 | 168 |
Trials on file
All 16 incretin trials recorded in this indication, active first.